Zamrini, Edward and Pekkonen, Eero and Maestú, Fernando and Funke, Michael and Makela, Jyrki and Myles, Riley and Bajo Breton, Ricardo and Sudre, Gustavo and Fernández, Alberto and Perales Castellanos, Nazareth and Pozo Guerrero, Francisco del and Stam, C.J. and Van Dijk, Bob W. and Bagic, Anto and Becker, James T.
Magnetoencephalography as a putative biomarker for Alzheimer's disease..
"International Journal of Alzheimer's Disease"
Alzheimer’s Disease (AD) is the most common dementia in the elderly and is estimated to aﬀect tens of millions of people worldwide. AD is believed to have a prodromal stage lasting ten or more years. While amyloid deposits, tau ﬁlaments, and loss of brain cells are characteristics of the disease, the loss of dendritic spines and of synapses predate such changes. Popular preclinical detection strategies mainly involve cerebrospinal ﬂuid biomarkers, magnetic resonance imaging, metabolic PET scans, and amyloid imaging. One strategy missing from this list involves neurophysiological measures, which might be more sensitive to detect alterations in brain function. The Magnetoencephalography International Consortium of Alzheimer’s Disease arose out of the need to advance the use of Magnetoencephalography (MEG), as a tool in AD and pre-AD research. This paper presents a framework for using MEG in dementia research, and for short-term research priorities